Short answer
Aura Biosciences, Inc. (AURA) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$32M
- −22.7% YoY · +29.7% QoQ
- EPS (diluted)
- −$0.24
- +36.8% YoY · +50.0% QoQ
Source: XBRL data from the Aura Biosciences, Inc. (AURA) Q3 2026 10-Q on SEC EDGAR. USD.
Aura Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved for sale
- Net loss $32.1M vs $26.1M YoY, operating expenses $35.1M vs $27.9M
- R&D $24.7M vs $22.2M, clinical trials $9.3M vs $6.9M, strongest spending area
- Cash, equivalents and marketable securities $297.2M, funding operations into first half of 2029
- Operating cash use $88.8M vs $64.3M, financing provided $242.3M after $280.8M offering proceeds and $39.0M repurchase
Risk Factors
- Pivotal Phase 3 enrollment completed, but topline data not expected until second half of 2027, delaying potential approval and commercialization
- EMA-required drug-substance characterization testing delayed Phase 3 enrollment authorization under EU Clinical Trial Regulation
- Single-source manufacturing for bel-sar regulatory materials, drug substance, and drug product heightens supply interruption risk
- Cash and marketable securities fund operations into first half of 2029, but additional capital needed to complete bel-sar development
- 2026 Sales Agreement permits up to $200.0 million in common-stock offerings, creating potential shareholder dilution
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aura Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.